In consultation with management, Microbix’s Board of Directors has approved the issuance of 2,600,000 options in accordance with the terms of the Stock Option Plan. The approved options are exercisable at a price of $0.23 per share, as determined by the closing price of the TSX on 20 February, 2026. Each option will vest and be exercisable after three years and have a total life of five years. The stock option grants form part of the total remuneration package for the recipients and are subject to TSX approval.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MBXBF:
- Microbix at an Operational and Financial Inflection Point: Sequential Rebound and Fading China Drag Support Buy Rating
- Microbix Biosystems Earnings Call Balances Pressure, Progress
- Microbix Q1 Revenue Rebounds Sequentially as China Antigen Sales Slide
- Microbix Q1 Revenue Rebounds Sequentially but China Slump Drives Loss
- Microbix Biosystems reports Q1 revenue C$4.22M vs. C$6.04M last year